E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major surgery when the use of paracetamol is required for pain release |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Main objective : Study the metabolism and the pharmacokinetics of acetaminophenadministered at maximal doses in post-op pediatric patients with relation to UDPglucuronyltransferase 1A1 (UGT1A1), cytochrome P450 2E1 and 1A2 (CYP2E1 and CYP1A2),and glutathion-S-transferase M1, P1 and T1 (GSTM1, GSTP1 and GSTT1) polymorphisms. |
|
E.2.2 | Secondary objectives of the trial |
Rationalize the empiric use of N-acetylcysteine to prevent acute liver failure. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provided signed written informed consent. 2. Boys or girls 2 to 8 years old 3. Patients after major surgery such as cardiac, orthopedic or digestive surgery whereacetaminophen is used in pain management or patients who require acetaminophentreatment for at least 3 days. 4. Nutritional status based on weight, height and skin fold thickness within the normal limits(as described on the growth curves given on the CDC's website :HTTP://www.cdc.gov/nchs/about/major/nhanes/growthcharts/datafiles.htm)5. The following laboratory parameters within the normal limitsa) non-conjugated serum bilirubin calculated with the following formula SNCB = STB – SCB where : SNCB = non conjugated serum bilirubin in mg/dLSTB = total serum bilirubin (nl : 0,3 à 1,2 mg/dL) SCB = conjugated serum bilirubin (nl < 0,2 mg/dL)b) aspartate aminotransferase (AST) (nl : 6-33UI/L) / alanine aminotransferase (ALT) (nl :14-63 UI/L)c) total alkaline phosphatase (ALP) (nl : 28-94 UI/L)d) INR (nl : 0,9-1,3) |
|
E.4 | Principal exclusion criteria |
1. Other serious illness or medical condition including:– Infection requiring systemic anti-infective therapy,– Any medical condition that might be aggravated by treatment or which couldn’t be controlled 2. Psychological, familial or sociological conditions which don’t allow medical follow-upand/or compliance with the study protocol. 3. Any hepatic disease which could lead to abnormal hepatic function 4. Any renal disease which could lead to abnormal renal function. 5. Inadequate renal function defined by a creatinine clearance < 60 mL/min Creatinine clearance is calculated using the Schwartz formula CLCR = (k x h)/SCRwhere :h = height in cmCLCR = creatinine clearance in ML/min/1.73m2k = 0,55 for children age 2-12SCR = serum creatinine in mg/dL6. Inadequate liver function defined by ALT/AST superior to twice ULN (upper limit normal)and INR prolonged 7. Prior allergic reaction to acetaminophen 8. Patients who require treatment with strong inhibitors of UGT1A1, including phenobarbital(gardenal® and mysoline®) and phenytoin (dyphantoïne® and épanutine®). 9. Patients who require treatment with activators of CYP2E1 and CYP1A2, including izoniazid(nicotibine®), insulin and omeprazole (docomépra®, logastric®, losec®, oméprasol®,omépratop® and sedacid®). 10. Patients who have received antipyretic drugs in the last 72 hours. 11. Participation in a clinical study with an investigational agent or device within 30 days. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety of acetaminophen administered at maximal doses in post-op pediatric patients |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |